Community Acquired PneumoniaNCT07317440
Coenzyme Q10 in Pediatric Community-Acquired Pneumonia
A study testing oral coenzymeQ10 in people with Community Acquired Pneumonia, run by Tanta University at 1 site in Egypt.
Trial summary
The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia Read more about this study
- Who is it for?
- Ages 2 months to 18 years
- Conditions the study is for
- Community Acquired Pneumonia
- What is being tested?
- oral coenzymeQ10
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteEgypt
- Study dates
- 31 Dec 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 months to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- All children aged 2 months -18 years with community acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x ray indicating community acquired pneumonia
Who cannot join
- Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders, children with CHD affecting the pulmonary blood flow.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Tanta University
Tanta, Gharbia Governorate, 37515
Rehab Zaki Elmeazawy, 01004815280
Ahmedelniny8@gmail.com
About this study
Official title: Coenzyme Q10 as an Adjunct Therapy in Pediatric Community-Acquired Pneumonia
The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia
- Conditions
- Community Acquired Pneumonia
- Being tested
- oral coenzymeQ10
- Medical subject headings
- Community-Acquired Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
oral coenzymeQ10Drug
60 children with community acquired pneumonia will receive oral coenzymeQ10 in capsule form at a dose of 100-200 mg/kg/day, as adjunct therapy to the usual pneumonia treatment till the recovery of the disease.
| Study group | Role | What they receive |
|---|---|---|
| 60 children with community acquired pneumonia will receive oral coenzymeQ10 | Experimental | Not described Receives: Drug: oral coenzymeQ10 |
| 60 children with community acquired pneumonia with the standard pneumonia treatment. | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Normalization of respiratory rate
Measured: 3 days
Normalization of temperature
Measured: 3 days
Normalization of oxygen saturation
Measured: 3 days
Normalization of Feeding Behavior Assessed by Oral Intake Tolerance
Normalization of feeding refusal will be assessed by evaluating the child's ability to tolerate age-appropriate oral feeding without refusal over a 3-day observation period.
Measured: 3 days
Serum C-Reactive Protein (CRP) Level
Blood samples will be collected, and CRP concentration will be expressed in milligrams per liter (mg/L).
Measured: 5 days
Serum Lactate Dehydrogenase (LDH) Level
LDH concentration will be reported in units per liter (U/L) from venous blood samples.
Measured: 5 days
Prognostic Nutritional Index
Measured: 5 days
Systemic Immune-Inflammation Index
Measured: 5 days
Serum C-Reactive Protein to Albumin Ratio (CRP/Albumin Ratio)
The serum C-reactive protein to albumin ratio (CRP/albumin ratio) will be calculated as a single composite outcome measure using laboratory values obtained from the same blood sample.
Measured: 5 days
Time of clinical stability
Measured: 3-5 days
Secondary outcomes (2)
Length of hospital stay
Measured: 10-21 days
Number of Participants Requiring Surgical Intervention
This outcome measures whether a participant undergoes any surgical intervention related to the study condition during the follow-up period. Surgical intervention is defined as any operative procedure performed under general or regional anesthesia, as documented in the medical record.
The outcome will be recorded as a binary variable (Yes/No) for each participant and summarized as the number and proportion of participants requiring surgical intervention.
Measured: 21-30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2026
- Study start31 Dec 2025 (estimated)
- Primary completion1 Jun 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Community Acquired PneumoniaStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rehab Zaki Elmeazawy, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07317440
- Sponsor's protocol ID
- 36264PR1169/3/25
- Status last verified
- Dec 2025
- First submitted
- 9 Jun 2025
- Last updated
- 5 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Coenzyme Q10 as an Adjunct Therapy in Pediatric Community-Acquired Pneumonia
- ClinicalTrials.gov ID
- NCT07317440
- Acronym / sponsor ID
- 36264PR1169/3/25
- Conditions
- Community Acquired Pneumonia
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 31 Dec 2025 (estimated)
- Primary completion
- 1 Jun 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 5 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 60 children with community acquired pneumonia will receive oral coenzymeQ10 | Experimental | Drug: oral coenzymeQ10 |
| 60 children with community acquired pneumonia with the standard pneumonia treatment. | No intervention | – |
Who may qualify
- Ages
- 2 months to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- All children aged 2 months -18 years with community acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x ray indicating community acquired pneumonia
Key exclusion criteria (1 listed)
- Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders, children with CHD affecting the pulmonary blood flow.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| oral coenzymeQ1060 children with community acquired pneumonia will receive oral coenzymeQ10 in capsule form at a dose of 100-200 mg/kg/day, as adjunct therapy to the usual pneumonia treatment till the recovery of the disease. | Drug | 60 children with community acquired pneumonia will receive oral coenzymeQ10 |
Primary outcome
Normalization of respiratory rate
Time frame: 3 days
Normalization of temperature
Time frame: 3 days
Normalization of oxygen saturation
Time frame: 3 days
Normalization of Feeding Behavior Assessed by Oral Intake Tolerance
Time frame: 3 days
Normalization of feeding refusal will be assessed by evaluating the child's ability to tolerate age-appropriate oral feeding without refusal over a 3-day observation period.
Serum C-Reactive Protein (CRP) Level
Time frame: 5 days
Blood samples will be collected, and CRP concentration will be expressed in milligrams per liter (mg/L).
Serum Lactate Dehydrogenase (LDH) Level
Time frame: 5 days
LDH concentration will be reported in units per liter (U/L) from venous blood samples.
Prognostic Nutritional Index
Time frame: 5 days
Systemic Immune-Inflammation Index
Time frame: 5 days
Serum C-Reactive Protein to Albumin Ratio (CRP/Albumin Ratio)
Time frame: 5 days
The serum C-reactive protein to albumin ratio (CRP/albumin ratio) will be calculated as a single composite outcome measure using laboratory values obtained from the same blood sample.
Time of clinical stability
Time frame: 3-5 days
2 secondary outcomes
Length of hospital stay
Time frame: 10-21 days
Number of Participants Requiring Surgical Intervention
Time frame: 21-30 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2026.
Related trials for Community Acquired Pneumonia
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
Not yet recruitingPhase 4
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
Community Acquired Pneumonia (CAP)
Active, not recruitingPhase 2/3
Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia
Community-acquired Pneumonia, CAP
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing oral coenzymeQ10 in people with Community Acquired Pneumonia, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ahmed Elniny Lecturer of Pediatrics, MD (01002219783, Ahmedelniny8@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Normalization of respiratory rate (time frame: 3 days). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2026.